Featured Research

from universities, journals, and other organizations

Mayo Clinic Investigates New Device To Regulate Beating Of The Heart And Improve Pump Function

Date:
November 1, 1999
Source:
Mayo Clinic
Summary:
Mayo Clinic cardiologists are investigating the use of a new pacemaker-defibrillator device that may offer new hope for patients with heart failure who also have potentially dangerous uncoordinated or irregular contractions of the heart.

ROCHESTER, MINN. -- Mayo Clinic cardiologists are investigating the use of a new pacemaker-defibrillator device that may offer new hope for patients with heart failure who also have potentially dangerous uncoordinated or irregular contractions of the heart.

Up to 50 percent of people with advanced heart failure develop abnormalities of the heart's electrical impulses, which disturb the timing of the contractions of the heart's two lower chambers, called ventricles, so that they do not contract simultaneously. When this occurs, the symptoms of heart failure, including shortness of breath, fatigue and swelling of the feet and ankles, may worsen, thereby decreasing the pumping efficiency of the heart.

"This device delivers small electrical impulses to the left and right chambers of the heart, to better synchronize the contractions of the heart's lower chambers," says Mayo Clinic cardiologist and study investigator, Paul Friedman, M.D. "We will investigate if this therapeutic approach improves the quality of life for patients with heart failure."

Until now, traditional heart failure therapies have included: medications, lifestyle modifications and heart transplant.

Heart failure affects about five million people in the United States. This debilitating disease is the most frequent cause of hospitalization for people age 65 and older, and often leads to premature death. Healthcare costs associated with caring for those with heart failure in the United States is nearly $10 billion annually.

The main purpose of the study is to assess the safety and effectiveness of the device in patients with heart failure who are also indicated for a traditional defibrillator and meet the other entry criteria.

The study will involve up to 35 investigational centers in the U.S. and will enroll 300 participants nationwide.

The device, which is the size of a small pager (66 cc), is implanted under the skin in the chest area, and three thin wires (called leads) are run through veins from the device to the left and right chambers of the heart. Only a small incision is required to implant the device. The procedures takes about two to three hours to perform and requires patients to stay in the hospital overnight.

Candidates for the study must have had at least one episode of cardiac arrest manifested by loss of consciousness due to an irregular heart beat, or have fast heart beats from the lower chambers (ventricular tachyarrhythmias). Some individuals who have pre-existing defibrillators in need of change out may also be eligible. Study participants are monitored at one month, three months, six months and every six months thereafter.

The study is expected to last between 12 and 24 months. Patients who are interested in participating in the study should contact electrophysiology clinical research at 507-255-3175 or 507-255-3177.

###

To receive Mayo news releases by e-mail, send a message to newsbureau@mayo.edu. Include your name, affiliation, and e-mail address. Mayo Clinic news releases are available on the Mayo Home Page, http://www.mayo.edu. Mayo Clinic health information is available on Mayo Clinic Health Oasis at http://www.mayohealth.org.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Mayo Clinic Investigates New Device To Regulate Beating Of The Heart And Improve Pump Function." ScienceDaily. ScienceDaily, 1 November 1999. <www.sciencedaily.com/releases/1999/11/991101075606.htm>.
Mayo Clinic. (1999, November 1). Mayo Clinic Investigates New Device To Regulate Beating Of The Heart And Improve Pump Function. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/11/991101075606.htm
Mayo Clinic. "Mayo Clinic Investigates New Device To Regulate Beating Of The Heart And Improve Pump Function." ScienceDaily. www.sciencedaily.com/releases/1999/11/991101075606.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins